Alnylam Pharmaceuticals Inc (ALNY)
243.25
+0.99
(+0.41%)
USD |
NASDAQ |
Dec 24, 16:00
Alnylam Pharmaceuticals Cash from Investing (Quarterly): -30.25M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Pfizer Inc | -2.057B |
| BridgeBio Pharma Inc | 38.23M |
| Gilead Sciences Inc | -710.00M |
| Regeneron Pharmaceuticals Inc | -574.40M |
| Sarepta Therapeutics Inc | -128.82M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 43.71M |
| Cash from Financing (Quarterly) | 102.76M |
| Free Cash Flow | 16.06M |
| Free Cash Flow Per Share (Quarterly) | 0.3073 |
| Free Cash Flow to Equity (Quarterly) | 38.55M |
| Free Cash Flow to Firm (Quarterly) | 41.80M |
| Free Cash Flow Yield | 0.05% |